21 insiders reported 295 Form 4 transactions for Apellis Pharmaceuticals, Inc. (APLS) over the past 18 months (most recent 2026-05-14). Recent activity: Deschatelets Pascal (Chief Scientific Officer) Sell 1.2M shares, Chopas James George (VP/Chief Accounting Officer) Buy 5,625 shares, Walbert Keli (Director) Sell 17,051 shares, FONTEYNE PAUL R. (Director) Sell 30,666 shares, Dolsten Mikael (Director) Sell 14,312 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Deschatelets Pascal | Chief Scientific Officer | Sell | 1.2M | $0 |
| 2026-05-14 | Chopas James George | VP/Chief Accounting Officer | Buy | 5,625 | $0 |
| 2026-05-14 | Walbert Keli | Director | Sell | 17,051 | $0 |
| 2026-05-14 | FONTEYNE PAUL R. | Director | Sell | 30,666 | $0 |
| 2026-05-14 | Dolsten Mikael | Director | Sell | 14,312 | $0 |
| 2026-05-14 | Boucher Kelley | Chief People Officer | Sell | 127,804 | $0 |
| 2026-05-14 | Machiels Alec | Director | Sell | 384,989 | $0 |
| 2026-05-14 | Nicholson Nur | Chief Technical Officer | Sell | 116,338 | $0 |
| 2026-05-14 | WHEELER CRAIG A | Director | Sell | 24,444 | $0 |
| 2026-05-14 | Dunlop A. Sinclair | Director | Sell | 161,567 | $0 |
| 2026-05-14 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 114,591 | $0 |
| 2026-05-14 | O'Brien Stephanie Monaghan | Director | Sell | 25,666 | $0 |
| 2026-05-14 | Baumal Caroline | Chief Medical Officer | Sell | 86,525 | $0 |
| 2026-05-14 | MELTZER LESLIE | Chief Research and Development | Sell | 107,024 | $0 |
| 2026-05-14 | Chan Gerald | Director | Sell | 25,666 | $0 |
| 2026-05-14 | Watson David O. | General Counsel | Sell | 144,517 | $0 |
| 2026-05-14 | Chopas James George | VP/Chief Accounting Officer | Sell | 65,955 | $0 |
| 2026-05-14 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 140,945 | $0 |
| 2026-05-14 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 71,492 | $0 |
| 2026-05-14 | MELTZER LESLIE | Chief Research and Development | Buy | 22,610 | $0 |
| 2026-05-14 | Chan Gerald | Director | Sell | 3,062 | $0 |
| 2026-05-14 | Watson David O. | General Counsel | Sell | 10,000 | $0 |
| 2026-05-14 | Dunlop A. Sinclair | Director | Sell | 3,062 | $0 |
| 2026-05-14 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Buy | 41,250 | $0 |
| 2026-05-14 | Francois Cedric | Chief Executive Officer | Sell | 425,968 | $0 |
Source: SEC Form 4 filings · as of 2026-05-14